Interferon-α in chronic hepatitis C infection in dialysis patients

Huraib, Sameer; Tanimu, Danlami; Romeh, Saleh Abu; Quadri, K; Ghamdi, Ghormullah Al; Iqbal, Aamir; Abdulla, A.

doi:10.1016/s0272-6386(99)70108-3

Cited by 65 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between immunosuppression and worsening of clinical disease in hepatitis C is well known (23). Various regimens, including interferon, have been attempted in the peritransplant course, with mixed results (24)(25)(26)(27)(28)(29). These studies also suggest that interferon treatment, especially after transplantation, may stimulate the immune system and lead to allograft rejection.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Batty¹,

Swanson²,

Kirk³

et al. 2001

Am J Transplant

View full text Add to dashboard Cite

National statistics for patient characteristics and survival of renal transplant recipients positive for hepatitis C virus (HCVπ 01 by log rank test). In Cox regression, mortality was higher for HCVπ (adjusted hazard ratio Ω 1.23, 95% confidence interval Ω 1.01-1.49, p Ω0.04). HCVπ recipients were more likely to be African-American, male, older, and to have received repeat transplants and donor HCVπ transplants. HCVπ recipients also had substantially longer waiting times for transplant. In contrast to recent studies, diabetes did not have an increased association with HCVπ , perhapsThe opinions are solely those of the authors and do not represent an endorsement by the Department of Defense. 179due to limitations of the database. HCVπ recipients had increased mortality and hospitalization rates compared with other transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Batty¹,

Swanson²,

Kirk³

et al. 2001

Am J Transplant

View full text Add to dashboard Cite

show abstract

“…On the other hand, these adverse effects generally disappeared completely with cessation of treatment. Among patients who had pre-and posttreatment liver biopsies, there was usually histological improvement as well (568,573,575). Thus, these results suggest that HCV-infected candidates with active HCV (indicated by RNA levels on polymerase chain reaction assay) should consider treatment with interferon alpha-2a.…”

Section: The Evaluation Of Renal Transplant Candidates: Clinical Pracmentioning

confidence: 84%

“…Several small trials have examined the safety and efficacy of interferon alpha-2a treatment of hemodialysis patients (566)(567)(568)(569)(570)(571)(572)(573)(574)(575). Two of the trials were randomized and controlled (569,574).…”

Section: The Evaluation Of Renal Transplant Candidates: Clinical Pracmentioning

confidence: 99%

See 1 more Smart Citation

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

2001

American Journal of Transplantation

View full text Add to dashboard Cite

“…Limited data based on inclusion criteria were imputed for the remaining four studies (43)(44)(45)(46), but no further data were provided despite multiple attempts to contact authors.…”

Section: Study Characteristicsmentioning

confidence: 99%

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Gordon¹,

Uhlig²,

Lau

et al. 2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: Hepatitis C virus (HCV) infection is prevalent in hemodialysis patientsResults: Twenty studies of IFN treatment provided data on 428 patients. Overall SVR was 45% and in univariate analyses was higher with: 1) three million units or higher three times weekly of IFN; 2) treatment for at least 6 mo; 3) treatment completion; 4) lower baseline HCV RNA; 5) female gender; and 6) early virological negativity. Although limited by missing data, these relationships persisted in multivariate regression.Conclusions: SVR is more likely with larger IFN dose, longer treatment duration, treatment completion, female gender, lower HCV RNA and early virological negativity. For appropriate treatment candidates, regimens should consist of three million units of IFN three times weekly for at least 6 mo, with patients encouraged to complete the full course.

show abstract

Interferon-α in chronic hepatitis C infection in dialysis patients

Cited by 65 publications

References 28 publications

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Contact Info

Product

Resources

About